Evaluating plasma extracellular vesicle microRNAs as possible biomarkers for osteoarthritis. Issue 3 (January 2020)

• Record Type: Journal Article
• Authors: Aae, Tommy Frøseth; Karlsen, Tommy Aleksander; Haugen, Ida K.; Risberg, May Arna; Lian, Øystein Bjerkestrand; Brinchmann, Jan E.
• Is Part Of: Osteoarthritis and cartilage open. Volume 1:Issue 3/4(2020)
• Publication Date: 2020-01
• Subjects: Articular cartilage -- Osteoarthritis -- microRNA -- Extracellular vesicles -- Biomarker; DE Differential Expression -- EVs Extracellular vesicles -- miRNAs MicroRNAs -- miR MicroRNA -- NGS Next Generation Sequencing -- OA Osteoarthritis -- TMM Trimmed mean of M-values; Osteoarthritis -- Periodicals; Cartilage -- Periodicals; 616.7223005
• DOI: 10.1016/j.ocarto.2019.100018
• Languages: English
• ISSNs: 2665-9131

Abstract

Summary: Objective: MicroRNAs (miRNAs) are being launched as biomarkers for various diseases, but a robust biomarker for articular cartilage pathology has yet to be discovered. Here we evaluate plasma extracellular vesicle (EV) miRNAs as possible biomarkers for osteoarthritis (OA). Method: We compared miRNA levels found in plasma EVs from patients with OA with controls without OA using next generation sequencing (NGS) technique. The patient and control pairs were matched for age, gender and body mass index. Results: 23 pairs of patients and controls were included. Patients with OA differed significantly from controls in both clinical and radiological assessment of OA. We identified 177 canonical miRNAs in plasma EVs, but found no difference in miRNA levels between the two groups. Interestingly, the concentration of each miRNA in plasma EVs showed minimal difference between the participants, suggesting that the release of miRNAs in EVs from cells within the various organs is a tightly controlled process. Conclusion: This is the first study using NGS in search of a miRNA biomarker in plasma EVs in OA. The levels of each plasma EVs miRNA were surprisingly similar for all participants. No plasma EVs miRNA can be used as a biomarker for OA.